No 02 2014

Swedish medtech company Getinge raised its adjusted EBITA margin to 15.1% in the third quarter of 2026, from 13.1% a year earlier, while organic sales grew 2.1%. The company kept its forecast of 3–5% organic sales growth for the full year.

Finnish pharmaceutical company Orion has upgraded its full-year 2026 outlook for both net sales and operating profit, as royalty income has grown faster than expected so far this year.

Swedish investment firm EQT has agreed to acquire diagnostics and life science tools company Qiagen through an all-cash public takeover offer, valuing the company at an enterprise value of about EUR 10.8 billion (USD 12.1 billion), including net debt.

Thomas Eldered, co-founder of Recipharm and founder of the investment company Flerie, has been appointed senior advisor to Sciety. He brings more than 35 years of experience from the pharmaceutical industry as an entrepreneur, executive, and investor.

Gesynta Pharma has completed enrollment in NOVA, its Phase II trial of the non-hormonal, non-opioid drug candidate vipoglanstat in endometriosis. The trial is fully enrolled more than three months ahead of schedule, and topline data are expected in the second quarter of 2027.

Finnish Faron Pharmaceuticals will present final survival data at ESMO 2026 from the melanoma cohort of its Phase 1/2 MATINS study. One in five patients achieved disease control on bexmarilimab alone, and these patients lived longer, although the difference was not statistically significant.

If you know what an NMT phone is, or, even more so, if you've ever used one, it's likely that you are formerly young. Slightly less so in Iceland, where well into the 2000s lots of the cool kids still had NMT phones in their jeeps. Your trusty Nokia 3310 could go several days on a charge, but drive away from a town or up a valley and the coverage quickly got spotty. With an NMT, though, you could head up toward the highlands or the upper reaches of a river and never be out of touch.